Fundraising Fox

aTYR PHARMA

NASDAQ: ATYR

San Diego, US · Delaware corporation · 6 known investors

atyrpharma.com ↗

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease. The company leverages a proprietary discovery platform targeting immune-mediated disorders in pulmonary and systemic conditions.

BiotechHealthtechMedical Devices

Founders & leadership

AN
Amir NashatNon-Management Director
PS
Paul SchimmelNon-Management Director
AS
Akkaraju SrinivasNon-Management Director
JD
John D. MendleinExecutive Officer, Director
DW
David WeinerExecutive Officer
EP
Ed PenhoetNon-Management Director
FC
Frederic ChereauExecutive Officer
KF
Kathryn FalbergNon-Management Director
JC
James C. BlairNon-Management Director
JK
John K. ClarkeNon-Management Director

Investors · 6

Cardinal PartnersPrincetonvia Paul Schimmel · board
EcoR1 CapitalSan Francisco
Sofinnova VenturesMenlo Park · $100K – $15M
Domain PartnersreportedPrinceton
Polaris PartnersreportedBoston · $500K – $5Mvia Amir Nashat · board
Samsara BioCapitalreportedPalo Altovia Srini Akkaraju · board

Reported raises · per SEC filings

Form D private placements
▶$45.8MraisedSep 2017 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey S. HatfieldDirector
  • John D. MendleinExecutive Officer, Director
  • John T. BlakeExecutive Officer
  • Amir H. Nashat, Sc.D.Director
  • Sanjay S. ShuklaExecutive Officer
  • Mark GoldbergDirector
  • Sanuj K. RavindranExecutive Officer
  • Nancy D. KruegerExecutive Officer
  • John K. ClarkeDirector
  • Paul SchimmelDirector
  • Srini AkkarajuDirector
  • Timothy P. CoughlinDirector
  • James C. BlairDirector
Offering amount
$45.8M
Amount sold
$45.8M
Sales commissions
$2.8M
Placement agents
Piper Jaffray & Co.
First sale
Aug 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$76.3MraisedApr 2015 · 42 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Amir NashatDirector
  • Paul SchimmelDirector
  • Akkaraju SrinivasDirector
  • John D. MendleinExecutive Officer, Director
  • David WeinerExecutive Officer
  • Ed PenhoetDirector
  • Frederic ChereauExecutive Officer
  • Kathryn FalbergDirector
  • James C. BlairDirector
  • John K. ClarkeDirector
Offering amount
$76.3M
Amount sold
$76.3M
First sale
Mar 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.